- Headquarters
- Rochester, Minnesota
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- vyriad.com
- Total Funding
- $95.0M
- Last Round
- $85.0M Series BDec 2025
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Vyriad is a clinical-stage biotechnology company founded by Mayo Clinic scientists developing engineered virus platforms for oncolytic virotherapy, in vivo gene therapy, and gene editing. The company's VSV and measles virus-based therapies are in Phase 1-2 clinical trials across multiple cancer types, with an ongoing strategic collaboration with Regeneron Pharmaceuticals.
Summary
VYRIAD INC is a Biotech company based in Rochester, United States, founded in 2017. It has raised $95.0M in total across 2 rounds, most recently a $85.0M Series B round in Dec 2025. Investors include Harry Stine, Mayo Clinic and Mirae Asset.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2025
Sign up to see all 2 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/vyriad-inc"><img src="https://indexed.vc/api/badge/company/vyriad-inc" alt="VYRIAD INC on Indexed.vc" width="260" height="76" /></a>